Sutro Biopharma Q2 revenue falls to $9.8 million; net loss widens to $38.5 million
Sutro Biopharma reported second quarter 2026 revenue of $9.8 million, down from $63.7 million a year earlier, and a net loss of $38.5 million, or $2.33 per share, versus a net loss of $11.5 million, or $1.35 per share, a year earlier. The company also reported $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it says supports operations into at least the second quarter of 2028.
Key points
- Q2 2026 revenue was $9.8 million, mainly from the Astellas collaboration, compared with $63.7 million in Q2 2025.
- Net loss was $38.5 million, or $2.33 per share, compared with $11.5 million, or $1.35 per share, in Q2 2025.
- Cash, cash equivalents and marketable securities were $164.3 million, down from $202.6 million as of March 31, 2026.
- Total R&D and G&A expenses were $39.5 million, down from $48.7 million a year earlier.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.